480
Views
2
CrossRef citations to date
0
Altmetric
Commentary

Erythropoiesis-stimulating agents in myelodysplastic syndromes

Pages 1155-1156 | Published online: 24 Jun 2010

References

  • Hellström-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008;45:14–22.
  • Mannone L, Gardin C, Quarre MC, et al; Groupe Francais des Myelodysplasies. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol 2006;133:513–519.
  • Jädersten M, Montgomery S, Dybedal I, Porwit-McDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment with granulocyte-CSF and erythropoietin for the anemia of myelodysplastic syndromes. Blood 2005;106:803–811.
  • Balleari E, Rossi E, Clavio M, et al Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006;85:174–180.
  • Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037–1046.
  • Malcovati L, Germing U, Kuendgen A, et al Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
  • Park S, Grabar S, Kelaidi C, et al GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574–582.
  • Jädersten M, Malcovati L, Porwit-McDonald A, Cazzola M, Hellström-Lindberg E. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. J Clin Oncol 2008;26:3607–3613.
  • Greenberg PL, Sun Z, Miller KB, et al Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114:2393–2400.
  • Oliva EN, Nobile F, Alimena G, et al Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010;51:1007–1014.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.